Narasimhan is confident that Novartis will achieve its goal of increasing sales by an average of 5% annually by 2028.

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...

Novartis AG (NYSE:NVS) raised its full-year guidance for the third time, indicating strong underlying business momentum. Key ...

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Reports Q3 revenue $12.82B, consensus $12.76B. Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered another quarter of ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.